Clinical Trial Update: Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating the safety and potential efficacy of the novel gene therapy ZM-02 in patients with retinitis pigmentosa, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• ZM-02

Snippet

Sponsor: Zhongmou Therapeutics | Conditions: Retinitis Pigmentosa | EARLY_Phase 1 | Status: RECRUITING